All Stories

  1. Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes
  2. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
  3. Tiered Training and Licensure for the Future of the Pharmacy Profession: Panacea or Pandora's Box?
  4. Data from Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study
  5. Supplemental Figure S1 from Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study
  6. Supplemental Table S1 from Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study
  7. Table 1 from Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study
  8. Table 2 from Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study
  9. A fair machine learning model to predict flares of systemic lupus erythematosus
  10. Training the Next Generation of Researchers to Advance Cancer Health Equity: Five Years of Experience from the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
  11. Racial disparities in analgesic and psychiatric medication use during end-of-life care in advanced-stage colorectal cancer: A Retrospective Cohort Study
  12. Implementation and evaluation of a stop the bleed program at a college of pharmacy
  13. Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment
  14. Structural factors and their influence on the use of novel antidiabetic agents: Making the case for increased awareness and access to clinical pharmacy services
  15. A change to the pathway: The Impact of the Supreme Court of the United States affirmative action decision on clinical pharmacy and a call to action for pharmacists
  16. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
  17. Data from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  18. Data from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  19. Supplemental Table 1 from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  20. Supplemental Table 1 from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  21. Supplemental Table 2 from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  22. Supplemental Table 2 from Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  23. Clinical pharmacists addressing social determinants of health needs and eliminating health disparities: Bystander or change agent?
  24. Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies
  25. Community Champions: The Crucial Contribution of an Independent Pharmacy in COVID-19 Vaccination Efforts in an Underserved Community
  26. Implementing innovative teaching strategies to promote student academic engagement in a critical care elective
  27. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans
  28. Curricular changes in times of crisis: Lessons learned
  29. Abstract A026: Disparities in the use of pain medication in patients with pancreatic cancer: Focus on racial and ethnic minorities
  30. Abstract A027: Evaluation of psychotropic medication usage patterns in patients with pancreatic cancer by race/ethnicity
  31. Abstract C026: Pharmacogenetics of pancreatic ductal adenocarcinoma: A review of racial disparities
  32. Evaluation of Potential Racial Disparities inCYP2C19‐Guided P2Y12Inhibitor Prescribing After Percutaneous Coronary Intervention
  33. A scoping review on the relationship between race/ethnicity and the receipt of supportive care medications during cancer treatment: Implications for the clinical pharmacist
  34. Impact of Piperacillin-Tazobactam Dosing in Septic Shock Patients Using Real-World Evidence: An Observational, Retrospective Cohort Study
  35. Pharmacoequity and the clinical pharmacist: Why not us, why not now!
  36. Cognitive Testing of PAINReportIt-Spanish in Monolingual Hispanic Adults
  37. Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty
  38. Abstract PO-270: Evaluation of attitudes, beliefs and influences and their impact on HPV vaccination rates among minority health science students
  39. Pharmacokinetics in patients requiring renal replacement therapy
  40. Abstract PO-056: The ReTOOL training program for underrepresented minority students: Best practices for virtual training in midst of COVID-19
  41. 1435: EVALUATION OF BLACK-WHITE RACIAL DISPARITIES IN SEPSIS PATIENTS TREATED WITH PIPERACILLIN-TAZOBACTAM
  42. Addressing challenges of providing remote inpatient clinical pharmacy services
  43. Ten recommendations to increase Black representation within pharmacy organization leadership
  44. Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course
  45. 853: Comparison of Common Piperacillin-Tazobactam Dosing Strategies in Patients With Septic Shock
  46. 892: Impact of a Multimedia Approach to Rapid Response Team Training in a Pharmacy Critical Care Elective
  47. COVID-19 Therapeutics: Making Sense of It All
  48. Abstract D057: Impact of antibiotic exposure on the overall survival in patients receiving immune checkpoint inhibitors: Does race matter?
  49. 1382
  50. 960
  51. Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock
  52. Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis
  53. Effect of prescriber peer comparison reports on fluoroquinolone use across a 16-facility community hospital system
  54. Recent Updates in the Pharmacological Management of Sepsis and Septic Shock: A Systematic Review Focused on Fluid Resuscitation, Vasopressors, and Corticosteroids
  55. 667
  56. Major publications in the critical care pharmacotherapy literature: January-December 2013
  57. Vasoactive Substances and Nutrition in Critical Care
  58. Vasoactive Substances and Nutrition in Critical Care
  59. Understanding Vasoactive Medications
  60. 914
  61. Abstracts and Index of Authors
  62. Improved outcome of ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus in a trauma population
  63. Ventriculoperitoneal Shunt Infections in Adult Patients
  64. Interpreting Laboratory Data
  65. Abstracts and Index of Authors
  66. Vasoactive Substances and Their Effects on Nutrition in the Critically Ill Patient
  67. Prevention, Recognition, and Management of Delirium in the Intensive Care Unit
  68. Evaluation of Recombinant Factor VIIa Off-Label Use at an Acute Care Hospital With Established Guidelines for Use